BioBlast Pharma to Present at the 27th Annual ROTH Investor Conference

TEL AVIV, Israel, March 5, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and Chief Executive Officer of BioBlast Pharma, will provide a corporate overview at the 27th Annual ROTH Conference.

ROTH Capital Markets Investor Conference
Date: March 10
Time: 9:00-9:30am Pacific Time
Location: Ritz Carlton, Dana Point, CA

About BioBlast Pharma Ltd.

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Founded in 2012, the company is rapidly building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable genetic diseases. The BioBlast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.comSource: BioBlast Pharma